Press release
BrainStorm Cell Therapeutics Expands Pipeline with the Initiation of a Study for Multiple Sclerosis
Proposed Trial Will Build on NurOwn(TM) Platform to Meet Unmet Needs of Patients with Neurodegenerative Disorders.NEW YORK & PETACH TIKVAH, ISRAEL, Mar 13, 2012 -- BrainStorm Cell Therapeutics Inc., a developer of adult stem cell technologies and CNS therapeutics, announces plans to initiate a preclinical study assessing the efficacy of its NurOwn(TM) stem cell technology in patients with Multiple Sclerosis (MS). Positive proof-of-concept results for MS have been confirmed in a set of in-vitro and in-vivo experiments, and the Company is working to advance MS into preclinical development in Q2 2012.
Based on initial promising pre-clinical data published by the Company's Chief Scientist, Prof. Daniel Offen of Tel Aviv University, BrainStorm has decided to explore MS as an additional indication for its NurOwn technology. The Company will draw plans to initiate pre-clinical safety trials, after which it will seek a leading medical center specializing in MS for clinical trials.
"We have been focused on growing our pipeline of indications using our NurOwn(TM) stem-cell technology," commented Dr. Adrian Harel, Acting CEO of BrainStorm Cell Therapeutics. "As we continue our ongoing trials to evaluate the safety, tolerability and therapeutic effects of NurOwn(TM) in ALS patients, we have determined through positive preliminary animal data that MS will be the next indication to pursue using our technology."
About NurOwn(TM) BrainStorm's core technology, NurOwn(TM), is based on the scientific achievements of Professor Eldad Melamed, former Head of Neurology, Rabin Medical Center, and Tel-Aviv University, and Professor Daniel Offen, Head of the Neuroscience Laboratory, Felsenstein Medical Research Center at the Tel-Aviv University.
The NurOwn(TM) technology processes adult human mesenchymal stem cells that are present in bone marrow and are capable of self-renewal as well as differentiation into many cell types. The research team is among the first to have successfully achieved the in-vitro differentiation of adult bone marrow cells (animal and human) into cells capable of releasing neurotrophic factors, such as glial-derived neurotrophic factor (GDNF), by means of a specific differentiation-inducing culture medium.
About Multiple Sclerosis (MS)
Multiple sclerosis (MS) is believed to be an autoimmune disorder that affects the central nervous system (CNS). Autoimmune means that the body's immune system mistakenly attacks its own tissue, in this case, the tissues of the CNS. With MS, autoimmune damage to neurons disrupts the body's ability to send and receive signals, thus causing MS-related symptoms.Symptoms may vary due to the location and extent of the damage. Worldwide, MS may affect more than 2 million individuals, including approximately 400,000 people in the United States.
About BrainStorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of adult stem cell therapeutic products derived from autologous bone marrow cells and intended for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn(TM) technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel-Aviv University. For more information, visit the company's website at http://www.brainstorm-cell.com.
Media Contact:
Janet Vasquez
IRG, LLC
1251 Avenue of the Americas, 20th Floor
New York, NY 10020
212-825-3210
jvasquez@investorrelationsgroup.com
http://www.irgnews.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release BrainStorm Cell Therapeutics Expands Pipeline with the Initiation of a Study for Multiple Sclerosis here
News-ID: 214122 • Views: …
More Releases from IRG, LLC
Trials Show Promise of Human Virus to Treat Head and Neck Cancer Patients
Leeds, UK - April 3, 2012 -- A naturally-occurring harmless human virus may be able to boost the effects of two standard chemotherapy drugs in some cancer patients, according to early stage trial data published today in Clinical Cancer Research.
RT3D, trade name Reolysin, is a new drug developed by Oncolytics Biotech Inc with preclinical and clinical studies conducted at The Institute of Cancer Research (ICR) and The Royal Marsden Hospital.…

NBA Fans Sure That Jeremy Lin Is For Real; In China, Thousands of His Jerseys Ar …
Stony Brook, NY (February 25, 2012) -- It took only 10 days for New York Knicks point guard Jeremy Lin to move from unknown Harvard grad to international, cover-of-Sports Illustrated sensation. That sent New York Times reporters scurrying downtown to discover whether the sharp-eyed basketball phenom had been paid the highest compliment: whether products associated with him, like jerseys and shoes, had been counterfeited and were being sold on the…
More Releases for NurOwn
Gene and Cell Therapies Targeting CNS Disorders Market Insight, Epidemiology and …
Gene and Cell Therapies Targeting CNS Disorders Market research report is the new statistical data source added by Infinity Business Insights.
Gene therapy, in particular, manipulates a patient's cells using genetic material, or DNA, to treat an inherited or acquired condition. Infusion or transplantation of entire cells into a patient for the treatment of an inherited or acquired disease is known as cell therapy.
Note – In order to provide more…
Bariatric Surgical Devices Market Therapeutic Survey Reviews, Analysis 2025
The report titled “Bariatric Surgical Devices Market” has recently added by MarketInsightsReports to get a stronger and effective business outlook. It provides an in-depth analysis of different attributes of industries such as trends, policies, and clients operating in several regions. The qualitative and quantitative analysis techniques have been used by analysts to provide accurate and applicable data to the readers, business owners, and industry experts.
The Bariatric Surgical Devices was valued…
Amyotrophic Lateral Sclerosis Pipeline - Key Players Analysis Flex Pharma, Orion …
The study analysed that the Amyotrophic lateral sclerosis pipeline comprises of 72 drug candidates in different stages of development.
Amyotrophic lateral sclerosis is a disease that causes progression in neurodegeneration in brain and spinal cord. In Amyotrophic lateral sclerosis, the muscle does not get adequate nourishment due to which it becomes atrophic. The disease occurs in the lateral region, an area in which spinal cord reflexes are found majorly. Therefore, the…
Amyotrophic Lateral Sclerosis Exhibits Emerging Pipeline with 60+ Drug Candidate …
The study analysed that the Amyotrophic lateral sclerosis pipeline comprises of 69 drug candidates, of which one drug candidate is in Phase III stage, 16 drug candidates are in Phase II stage, nine drug candidates are in Phase I stage, 32 drug candidates are in Pre-Clinical stage, five candidates are inactive and six drug candidates are in discontinued stage. Amyotrophic lateral sclerosis is a neurodegenerative disorder in brain and spinal…
Stem Cells Market Annual Sales of Advanced Cell Technology by 2018
Stem Cells Market: Overview
The rising funding from numerous governments and private organizations globally and the rising inclination toward stem cell research are amongst the prime factors boosting the growth of the global stem cells market. The emergence of numerous stem cell therapies also represent huge development opportunities for the key players in the stem cells market. In addition, the increasing demand for regenerative treatment options globally will positively impact the…
Global Amyotrophic Lateral Sclerosis Market Analysis,Forecast Clinical Trials Re …
MarketResearchReports.Biz presents this most up-to-date research on " Amyotrophic Lateral Sclerosis Global Clinical Trials Review, H2, 2016 "
GlobalData's clinical trial report, Amyotrophic Lateral Sclerosis Global Clinical Trials Review, H2, 2016" provides an overview of Amyotrophic Lateral Sclerosis clinical trials scenario. This report provides top line data relating to the clinical trials on Amyotrophic Lateral Sclerosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted…